|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schneider KA: All about breast
cancerCounseling About Cancer: Strategies for Genetic Counseling.
Wiley-Blackwell; Hoboken, NJ: pp. 151–185. 2011, View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boyd NF, Martin LJ, Bronskill M, Yaffe MJ,
Duric N and Minkin S: Breast tissue composition and susceptibility
to breast cancer. J Natl Cancer Inst. 102:1224–1237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ripperger T, Gadzicki D, Meindl A and
Schlegelberger B: Breast cancer susceptibility: Current knowledge
and implications for genetic counselling. Eur J Hum Genet.
17:722–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osborne CK and Schiff R: Mechanisms of
endocrine resistance in breast cancer. Annu Rev Med. 62:233–247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mueller KL, Yang ZQ, Haddad R, Ethier SP
and Boerner JL: EGFR/Met association regulates EGFR TKI resistance
in breast cancer. J Mol Signal. 5:82010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrer-Soler L, Vazquez-Martin A, Brunet
J, Menendez JA, De Llorens R and Colomer R: An update of the
mechanisms of resistance to EGFR-tyrosine kinase inhibitors in
breast cancer: Gefitinib (Iressa)-induced changes in the expression
and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J
Mol Med. 20:3–10. 2007.PubMed/NCBI
|
|
11
|
Mowafy S, Farag NA and Abouzid KAM:
Design, synthesis and in vitro anti-proliferative activity of
4,6-quinazolinediamines as potent EGFR-TK inhibitors. Eur J Med
Chem. 61:132–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lo HW, Hsu SC and Hung MC: EGFR signaling
pathway in breast cancers: From traditional signal transduction to
direct nuclear translocalization. Breast Cancer Res Treat.
95:211–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh UP and Bhat HR: PUB081 Discovery of
1,3,5-triazine based novel EGFR-tyrosine kinase inhibitor against
human lung carcinoma. J Thor Oncol. 12(Suppl): S1494–S1495. 2017.
View Article : Google Scholar
|
|
14
|
Giacomelli G, Porcheddu A and De Luca L:
[1,3,5]-triazine: A versatile heterocycle in current applications
of organic chemistry. Curr Org Chem. 8:1497–1519. 2004. View Article : Google Scholar
|
|
15
|
Singh B, Bhat HR, Kumawat MK and Singh UP:
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as
antibacterial and antibiofilm agent against pathogens causing human
diseases with favorable metabolic fate. Bioorg Med Chem Lett.
24:3321–3325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dubey V, Pathak M, Bhat HR and Singh UP:
Design, facile synthesis, and antibacterial activity of hybrid
1,3,4-thiadiazole-1,3,5-triazine derivatives tethered via -S-
bridge. Chem Biol Drug Des. 80:598–604. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maarouf AR, Farahat A, Selim KB and Eisa
HM: Synthesis and antiviral activity of benzimidazolyl- and
triazolyl-1,3,5-triazines. Med Chem Res. 21:703–710. 2012.
View Article : Google Scholar
|
|
18
|
Singh UP, Bhat HR and Gahtori P:
Antifungal activity, SAR and physicochemical correlation of some
thiazole-1,3,5-triazine derivatives. J Mycol Med. 22:134–141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhat HR, Singh UP, Yadav PS, Kumar V,
Gahtori P, Das A, Chetia D, Prakash A and Mahanta J: Synthesis,
characterization and antimalarialactivity of
hybrid4-aminoquinoline-1,3,5-triazinederivatives. Arabian J Chem.
9(Suppl): S625–S631. 2016. View Article : Google Scholar
|
|
20
|
Bhat HR, Singh UP, Gahtori P, Ghosh SK,
GogoiKabita, Prakash A and Singh RK:
4-Aminoquinoline-1,3,5-triazine: Design, synthesis, in vitro
antimalarial activity and docking studies. New J Chem.
37:2654–2662. 2013. View Article : Google Scholar
|
|
21
|
Srivastava JK, Dubey P, Singh S, Bhat HR,
Kumawat MK and Singh UP: Discovery of novel
1,3,5-triazine-thiazolidine-2,4-diones as dipeptidyl peptidase-4
(DPP-4) inhibitor targeting S1 pocket for the treatment of type 2
diabetes along with antibacterial activity. RSC Adv. 5:14095–14102.
2015. View Article : Google Scholar
|
|
22
|
Srivastava JK, Awatade NT, Bhat HR, Kmit
A, Mendes K, Ramos M, Amaral MD and Singh UP: Pharmacological
evaluation of hybrid thiazolidin-4-one-1,3,5-triazines for NF-κB,
biofilm and CFTR activity. RSC Adv. 5:88710–88718. 2015. View Article : Google Scholar
|
|
23
|
Nie Z, Perretta C, Erickson P, Margosiak
S, Lu J, Averill A, Almassy R and Chu S: Structure-based design and
synthesis of novel macrocyclicpyrazolo[1,5-a] [1,3,5]triazine
compounds as potent inhibitors of protein kinase CK2 and their
anticancer activities. Bioorg Med Chem Lett. 18:619–23. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ertl P, Rohde B and Selzer P: Fast
calculation of molecular polar surface area as a sum of
fragment-based contributions and its application to the prediction
of drug transport properties. J Med Chem. 43:3714–3717. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pervez A, Meshram J, Tiwari V, Sheik J,
Dongre R, Youssoufi MH and Ben Hadda T: Pharmacophores modeling in
terms of prediction of theoretical physico-chemical properties and
verification by experimental correlations of novel coumarin
derivatives produced via Betti's protocol. Eur J Med Chem.
45:4370–4378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bikadi Z and Hazai E: Application of the
PM6 semi-empirical method to modeling proteins enhances docking
accuracy of AutoDock. J Cheminform. 1:152009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morris GM, Goodsell DS, Halliday RS, Huey
R, Hart WE, Belew RK and Olson AJ: Automated docking using a
Lamarckian genetic algorithm and an empirical binding free energy
function. J Comput Chem. 19:1639–1662. 1998. View Article : Google Scholar
|
|
28
|
Solis FJ and Wets RJB: Minimization by
random search techniques. Math Operat Res. 6:19–30. 1981.
View Article : Google Scholar
|
|
29
|
Lipinski CA, Lombardo F, Dominy BW and
Feeney PJ: Experimental and computational approaches to estimate
solubility and permeability in drug discovery and development
settings. Adv Drug Deliv Rev. 46:3–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ,
Kim YJ, Kim JH, Kang E, Kim SW, Kim IA and Park SY: High EGFR gene
copy number predicts poor outcome in triple-negative breast cancer.
Mod Pathol. 27:1212–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Srivastava JK, Pillai GG, Bhat HR, Verma A
and Singh UP: Design and discovery of novel
monastrol-1,3,5-triazines as potent anti-breast cancer agent via
attenuating epidermal growth factor receptor tyrosine kinase. Sci
Rep. 7:58512017. View Article : Google Scholar : PubMed/NCBI
|
